Newsroom
Labcorp (LH) Exceeds Q2 Earnings Expectations and Boosts Full-Year Guidance
By KlickAnalytics Data Insights | August 1, 2024 08:07PM ET
Key Points
- Labcorp (LH) surpasses second-quarter earnings and revenue estimates
- Labcorp (LH) reports adjusted EPS of $3.94 for Q2 2024
- Labcorp (LH) raises full-year revenue and EPS guidance
- Labcorp (LH) introduces new tests in specialty testing areas
- Labcorp (LH) launches Labcorp Global Trial Connect for clinical trials
Labcorp (LH) delivered strong financial results in the second quarter of 2024, surpassing both earnings and revenue estimates. The company reported an adjusted EPS of $3.94, a notable increase from $3.42 in the same quarter last year, outperforming the consensus of $3.78.
The positive earnings performance was driven by robust momentum as Labcorp (LH) continues to establish a strong position in the healthcare sector. Analysts have highlighted the company's solid performance and its ability to meet and exceed Wall Street expectations.
In addition to beating earnings estimates, Labcorp (LH) also saw an increase in margins, further demonstrating its financial strength and operational efficiency. The company's stock soared after the second-quarter results were announced, reflecting investor confidence in Labcorp's performance.
Looking ahead, Labcorp (LH) has raised its full-year guidance for 2024, projecting a revenue growth range of 6.4% to 7.5%. The updated guidance includes the impact of approximately 1.0% from Invitae, emphasizing Labcorp's commitment to delivering strong financial results for the year.
In line with its focus on innovation, Labcorp (LH) has introduced important new tests in specialty testing areas, showcasing its commitment to providing comprehensive laboratory services. Additionally, the company has launched Labcorp Global Trial Connect, a suite of central laboratory solutions designed to accelerate clinical trials and improve efficiency in the research process.
Overall, Labcorp (LH) has demonstrated strong performance in the second quarter of 2024, exceeding expectations and showcasing its leadership in the healthcare sector. With an increase in margins, raised full-year guidance, and a focus on innovation, Labcorp is well-positioned for continued growth and success in the future.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with